×

Uh-oh, it looks like your Internet Explorer is out of date.

For a better shopping experience, please upgrade now.

Approaches in Developing Human Antibodies and Antibody Fragments
     

Approaches in Developing Human Antibodies and Antibody Fragments

by William J. Harris, C Cunningham
 
Antibody Therapeutics is a comprehensive evaluation of progresstoward using humanized antibodies as a new generation of therapeutics. The humanized antibodies that have led the way in product approval are discussed as case studies, offering an insight into the preclinical and clinical data acquired during the regulatory approval process. Leading experts offer their

Overview

Antibody Therapeutics is a comprehensive evaluation of progresstoward using humanized antibodies as a new generation of therapeutics. The humanized antibodies that have led the way in product approval are discussed as case studies, offering an insight into the preclinical and clinical data acquired during the regulatory approval process. Leading experts offer their findings as examples of what works and what does not, saving you time and making your research more cost effective. This book is essential reading for researchers, clinicians, development and regulatory staff in pharmaceutical and biotechnology companies, and hospital staff, including policy and decision makers. It also provides postgraduate and medical students with an authoritative overview of the field.

Editorial Reviews

Doody's Review Service
Reviewer: John A. Robinson, MD (Loyola University Stritch School of Medicine)
Description: This is a duo-authored monograph written at the technical level by two PhDs in the field that discusses the current status and attempts to predict the future of the rapidly changing field of antibody therapeutics.
Purpose: It is comforting to know that scientific ingenuity is alive and well and especially manifest in the rapidly developing new methods on how to create and manufacture antibodies for diagnosis and therapy.
Audience: This book will be a helpful source for the interested neophyte, immunoengineer, or immunologist who wants to keep current in a very complex subfield of immunobiology.
Features: This book could have benefited from the addition of some clinical perspective. A striking example of this deficiency is the rather benign neglect of the extensively documented cytokine storm that occurs early during OKT3 therapy, CMV infection/reactivation, and the probable increased incidence of posttransplant lymphoproliferative disease with the use and overuse of this anti T-cell monoclonal. There is at least one serious typographical error designating the wrong CD for OKT3 in a table, but, on the other hand, several very helpful color illustrations that greatly facilitated the understanding of humanized antibodies, etc. have been included. Although the publisher states that this series of books is published 60 to 90 days after acceptance of the manuscripts, it is still clear that timeliness of the manuscripts are still a problem. Most of the discussion in this book is relevant to clinical trials completed at least two or more years before publication.
Assessment: On the whole, I recommend this book as a way to introduce oneself to the wonderful world of gene and protein engineering or to develop a perspective of a very difficult but potentially therapeutic revolution in clinical medicine.
3 Stars from Doody
John A. Robinson
This is a duo-authored monograph written at the technical level by two PhDs in the field that discusses the current status and attempts to predict the future of the rapidly changing field of antibody therapeutics. It is comforting to know that scientific ingenuity is alive and well and especially manifest in the rapidly developing new methods on how to create and manufacture antibodies for diagnosis and therapy. This book will be a helpful source for the interested neophyte, immunoengineer, or immunologist who wants to keep current in a very complex subfield of immunobiology. This book could have benefited from the addition of some clinical perspective. A striking example of this deficiency is the rather benign neglect of the extensively documented cytokine storm that occurs early during OKT3 therapy, CMV infection/reactivation, and the probable increased incidence of posttransplant lymphoproliferative disease with the use and overuse of this anti T-cell monoclonal. There is at least one serious typographical error designating the wrong CD for OKT3 in a table, but, on the other hand, several very helpful color illustrations that greatly facilitated the understanding of humanized antibodies, etc. have been included. Although the publisher states that this series of books is published 60 to 90 days after acceptance of the manuscripts, it is still clear that timeliness of the manuscripts are still a problem. Most of the discussion in this book is relevant to clinical trials completed at least two or more years before publication. On the whole, I recommend this book as a way to introduce oneself to the wonderful world of gene and protein engineering or to develop a perspective of a verydifficult but potentially therapeutic revolution in clinical medicine.
Booknews
Fifteen chapters evaluate progress toward using humanized antibodies as a new generation of therapeutics. The humanized antibodies that have led the way in product approval are discussed as case studies, offering an insight into the preclinical and clinical data acquired during the regulatory approval process. Contributors offer their findings as examples of what works and what doesn't, and provide critical appraisals of the progress and limitations to the use of humanized antibodies in infectious disease, immune suppression, autoimmune disease, and cancer. Annotation c. by Book News, Inc., Portland, Or.

Product Details

ISBN-13:
9781570592720
Publisher:
Landes Bioscience
Publication date:
01/01/1995
Series:
Molecular Biology Intelligence Unit Series
Pages:
153

Customer Reviews

Average Review:

Post to your social network

     

Most Helpful Customer Reviews

See all customer reviews